From: karkan@msdrl.com (Jim Karkanias)
Subject: Biomedical Engineer seeks employment in SF Bay area
Organization: Merck Research Laboratories
Date: Thu, 30 Jul 92 21:39:48 GMT

NAME:          CHRIS D. KARKANIAS
               Married to Cherolyn Karkanias, M.D.

ADDRESS:       160 North Gulph Road
               Suite 204NBS
               King of Prussia, PA  19406
               215-630-6010 (home)
               215-834-2842 (work)

EDUCATION:
               Bachelor of Science, Neurobiology and Behavior
               Rutgers University
               GPA in major: 3.735
               May 1986

               M.S., Bioengineering
               Drexel University - Bioengineering
               GPA: 4.000
               To be conferred: Jan. 1993

               Ph.D., Biomedical Engineering
               Drexel University - Bioengineering
               Temple University - School of Medicine
               GPA:  4.000
               To be conferred: June 1994


EXPERIENCE:

     Biomedical Engineer                         07/90 - present
     ===========================================================
          Institute of Biomedical Engineering at Drexel
          and Temple Medical School
               Completing research in the Department of          
               Pharmacology at Temple Medical School.            
               Affiliations with Drexel Biomedical Engineering   
               Institute and Department of Neuropsychology.      
               Current research areas concern the elucidation of 
               nociceptive mechanisms, learning and memory       
               mechanics, neuroplasticity, and their             
               interrelationship with endogenous reinforcement   
               systems, and the so-called primitive, "automatic" 
               systems (e.g. vestibular, cerebellar reflexes,    
               blindsight mechanics, etc.).  Coordinating        
               research in the areas of implantable biomedical   
               devices and the separate areas of biotechnology   
               and DNA/RNA-based therapy.


     Medical Program Coordinator                 07/88 - present
     ===========================================================
          Merck, Sharp, and Dohme
               Conduct and design of many clinical research      
               programs in the fields of schizophrenia,          
               analgesia, epilepsy/seizure, panic               
               disorder/anxiety, anorexia, ischemia/stroke, and  
               cancer/cell proliferation. Most programs involving 
               large multicenter studies at both domestic and    
               international sites. Excellent understanding of   
               Phase I to Phase V drug development process (i.e. 
               FDA requirements) as well as requirements of many 
               European Community Countries (ECC).


     Computer Skills                             11/82 - present
     ===========================================================
               Highly computer literate.  Knowledge of many high
               and low level computer languages (e.g. C, 80x86   
               and 680x0 assembly, PL/1, 4GLs, etc.).  Intimately 
               familiar with many hardware platforms (e.g. DEC   
               PDP-11, 80x86 and 680x0 CPUs, etc.) and operating 
               systems (e.g. MS-DOS, Windows, Unix, A/UX,        
               Macintosh OS, Amiga OS, SUN OS, Solaris, and      
               NeXTStep).  Excellent working knowledge of many   
               applications across many platforms (comprehensive 
               list available upon request).


Prior Experience

     Biologist                                   12/87 - 07/88
     ===========================================================
          Merck, Sharp, and Dohme
               Primarily responsible for the evaluation and      
               design of animal and tissue models of disease     
               states.  Main tasks involved the determination of 
               the pharmaceutical parameters of a given drug     
               candidate.  High degree of experience with all    
               facets of animal experimentation (i.e. preclinical 
               work) which lends me a unique perspective to      
               clinical research and the drug development        
               process.

     Clinical Research Associate                 11/86 - 12/87
     ===========================================================
          McNeil Pharmaceutical
               Initial exposure to clinical research occurred    
               here.  Primarily responsible for overseeing some  
               portions of a large study in depression. Wrote a  
               suite of programs to automate drug supply         
               tracking.


     Research Assistant                          09/83 - 11/86
     =========================================================== 
          McNeil Pharmaceutical
          Rutgers University
               Initial exposure to research and laboratory work.

PUBLICATIONS
============

D. Cooper, Chris D. Karkanias, and Gregory E. Martin.  The
Unilaterally Caudectomized Mouse: A Simple in vivo Test for
Dopamine Receptor Interactions.  Neuroscience, 1985

Charles R. Bowden and Chris D. Karkanias.  Food Intake of Rats is
not Decreased by Cyclo(histidyl-proline).  Federation
Proceedings, 1986

Charles R. Bowden, Chris D. Karkanias, and Andrew J. Bean. 
Re-Evaluation of Histidyl-Proline
Diketopiperazine[Cyclo(His-Pro)] Effects on Food Intake in the
Rat.  Pharm. Biochem. and Behav., 29:357-363, 1988

Linda L. Ng and Chris D. Karkanias.  Computerized Data Processing
and Validation in a Drug Delivery Laboratory.  American
Association of Pharmaceutical Scientists (AAPS), 1988

Alice E. Loper, Chris D. Karkanias, and Joseph V. Bondi.  Local
Skin Concentrations of (+)-PHNO, a Dopamine Agonist, Beneath
Transdermal Patches in Yucatan Miniature Swine.  
American Association of Pharmaceutical Scientists (AAPS), 1989

Chris D. Karkanias, Gilbert A. Block, Scott A. Reines, and
Jacques Bradwejn.
The Neurobiology of Panic Disorder
American Journal of Psychiatry, 1989

Jacques Bradwejn, Diana Koszycki, Lawrence Annable, Anne
Couetoux-Dutertre, Scott A. Reines, Chris D. Karkanias.
A dose-ranging study of the behavioral and cardiovascular effects
of CCK-tetrapeptide in Panic Disorder (submitted to Biological
Psychiatry)

Augustine Legido, Martin W. Adler, Chris D. Karkanias, Ellen B.
Geller, et al. Cholecystokinin (CCK) potentiates morphine
anticonvulsant action through both brain CCKA and CCKB receptors
(submitted to European Journal of Pharmacology)

Chris D. Karkanias, Scott A Reines, Michael Traub, et al.  The
effects of CCK antagonism on CCK-4 challenge in patients with
Panic Disorder (in process)

Chris D. Karkanias, Thomas Pellagro, Ellen B. Geller, and Martin
W. Adler  The Effects of Cholecystokinin and Cholecystokinin
Antagonists in the Cold Water Tail Flick Model.  (in process)

Chris D. Karkanias.  The role of Substance P in Analgesia.  (in
process)

Additional information or references are available upon request.